AVROBIO Stock Price, News & Analysis (NASDAQ:AVRO) $1.32 +0.10 (+8.20%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$1.21▼$1.3250-Day Range$1.22▼$1.6252-Week Range$0.57▼$1.93Volume321,108 shsAverage Volume1.33 million shsMarket Capitalization$58.83 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media AVROBIO MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside203.0% Upside$4.00 Price TargetShort InterestHealthy2.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.58 to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector399th out of 949 stocksBiological Products, Except Diagnostic Industry69th out of 163 stocks 3.3 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, AVROBIO has a forecasted upside of 203.0% from its current price of $1.32.Amount of Analyst CoverageAVROBIO has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.52% of the float of AVROBIO has been sold short.Short Interest Ratio / Days to CoverAVROBIO has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVROBIO has recently decreased by 58.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVRO. Previous Next 2.8 News and Social Media Coverage News SentimentAVROBIO has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AVROBIO this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions59.95% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to decrease in the coming year, from $0.58 to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AVROBIO Stock (NASDAQ:AVRO)AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More AVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVRO Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comAVROBIO (NASDAQ:AVRO) Stock Price Down 0.8%November 14, 2023 | morningstar.comAvrobio Inc AVRODecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | markets.businessinsider.comPotential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for AvrobioNovember 8, 2023 | finance.yahoo.comIs AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?October 6, 2023 | finance.yahoo.comHas AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?October 5, 2023 | msn.comAvroBio (AVRO) Price Target Increased by 12.82% to 3.74September 25, 2023 | ca.finance.yahoo.comAVROBIO, Inc. (AVRO)December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 11, 2023 | benzinga.comSolu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive OfficerAugust 12, 2023 | msn.comAvrobio: Net-Net Biotech Pursuing Strategic AlternativesAugust 11, 2023 | markets.businessinsider.comAvrobio (AVRO) Gets a Buy from BarclaysAugust 7, 2023 | finance.yahoo.comArbor Biotechnologies Appoints Deanna M. Petersen as Chief Business OfficerJuly 13, 2023 | nasdaq.comWells Fargo Maintains AvroBio (AVRO) Overweight RecommendationJuly 13, 2023 | finance.yahoo.comAVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%July 13, 2023 | bizjournals.comFive things you need to know today, and the Sumner Tunnel closure’s real testJuly 12, 2023 | benzinga.comWedbush Downgrades Avrobio to Neutral, Announces $2 Price TargetJuly 12, 2023 | seekingalpha.comAvrobio to explore strategic options; halts studiesJuly 12, 2023 | msn.comWhy Avrobio Shares Are Rising WednesdayJuly 12, 2023 | marketwatch.comAvrobio Shares Rise 38% After Move to Explore Strategic AlternativesJuly 12, 2023 | msn.comWedbush Downgrades AvroBio (AVRO)July 12, 2023 | bizjournals.comGene therapy startup Avrobio explores a saleJuly 12, 2023 | markets.businessinsider.comAVROBIO To Conduct Exploration Of Strategic Alternatives - Quick FactsJuly 12, 2023 | finance.yahoo.comAVROBIO to Explore Strategic AlternativesJune 28, 2023 | finance.yahoo.comAVRO - AVROBIO, Inc.June 27, 2023 | fool.comAvrobio (NASDAQ: AVRO)June 12, 2023 | seekingalpha.comAvrobio completes sale of gene therapy program to Novartis for $87.5MSee More Headlines Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+203.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio2.28 P/E GrowthN/ANet Income$-105,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.36% Return on Assets-79.74% Debt Debt-to-Equity RatioN/A Current Ratio14.44 Quick Ratio14.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.57Miscellaneous Outstanding Shares44,570,000Free Float40,473,000Market Cap$58.83 million OptionableNot Optionable Beta1.39 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Erik John Ostrowski M.B.A. (Age 51)President, Interim Chief Executive Officer, CFO & Treasurer Comp: $947.29kMs. Azadeh Golipour Ph.D. (Age 44)Chief Technology Officer Comp: $728.21kMr. Jeffrey Medin Ph.D.Scientific FounderMr. Steven N. Avruch J.D. (Age 62)Chief Legal Officer & Secretary Comp: $506.68kMr. Scott GottesmanVice President of Human ResourceMr. Andreas KouriSenior Vice President of Global Supply Chain & External ManufacturingDr. Essra Ridha FFPM (Age 42)M.D., Chief Medical Officer Ms. Kirsten DupuisChief of StaffMore ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHACardiff OncologyNASDAQ:CRDFCompugenNASDAQ:CGENSolid BiosciencesNASDAQ:SLDBEstrella ImmunopharmaNASDAQ:ESLAView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 500,000 shares on 11/15/2023Ownership: 1.123%Newtyn Management LLCBought 2,000,000 shares on 11/14/2023Ownership: 4.491%Terrapin Asset Management LLCBought 558,787 shares on 11/14/2023Ownership: 1.255%Acadian Asset Management LLCSold 45,058 shares on 11/13/2023Ownership: 3.874%Aldebaran Capital LLCBought 470,130 shares on 11/13/2023Ownership: 1.056%View All Institutional Transactions AVRO Stock Analysis - Frequently Asked Questions Should I buy or sell AVROBIO stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVRO shares. View AVRO analyst ratings or view top-rated stocks. What is AVROBIO's stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts. How have AVRO shares performed in 2023? AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 85.2% and is now trading at $1.32. View the best growth stocks for 2023 here. Are investors shorting AVROBIO? AVROBIO saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 964,900 shares, a drop of 58.2% from the October 31st total of 2,310,000 shares. Based on an average trading volume of 343,700 shares, the short-interest ratio is presently 2.8 days. Currently, 2.5% of the company's shares are sold short. View AVROBIO's Short Interest. When is AVROBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AVRO earnings forecast. How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.21. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS). When did AVROBIO IPO? (AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. Who are AVROBIO's major shareholders? AVROBIO's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (8.99%), Newtyn Management LLC (4.49%), Acadian Asset Management LLC (3.87%), Terrapin Asset Management LLC (1.25%), Affinity Asset Advisors LLC (1.12%) and Aldebaran Capital LLC (1.06%). View institutional ownership trends. How do I buy shares of AVROBIO? Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AVRO) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.